See more : Tacheng Real Estate Co.,Ltd. (6171.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Skinvisible, Inc. (SKVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Skinvisible, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- Tecan Group AG (TECN.SW) Income Statement Analysis – Financial Results
- The Aaron’s Company, Inc. (AAN) Income Statement Analysis – Financial Results
- ARTERIA Networks Corporation (4423.T) Income Statement Analysis – Financial Results
- M3 Mining Limited (M3M.AX) Income Statement Analysis – Financial Results
- Field Solutions Holdings Limited (FSG.AX) Income Statement Analysis – Financial Results
Skinvisible, Inc. (SKVI)
Industry: Household & Personal Products
Sector: Consumer Defensive
Website: https://www.skinvisible.com
About Skinvisible, Inc.
Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company offers sunless tanning and sunscreen products under the Skinbrella name. It also licenses to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.00K | 279.30K | 663.43K | 275.56K | 43.17K | 69.35K | 629.03K | 108.89K | 174.64K | 54.92K | 66.70K | 270.30K | 180.19K | 229.18K | 287.27K | 767.60K | 777.69K | 691.45K | 850.28K | 519.97K | 193.99K | 183.69K | 55.80K | 37.63K | 200.00K | 12.27K |
| Cost of Revenue | 0.00 | 4.81K | 3.30K | -122.92B | 17.55K | 20.70K | 42.31K | 37.06K | 56.90K | 26.49K | 2.17K | 4.63K | 1.68K | 19.46K | 51.46K | 23.12K | 140.88K | 77.47K | 140.40K | 96.78K | 136.13K | 50.13K | 8.29K | -59.41K | 0.00 | 4.00K |
| Gross Profit | 20.00K | 274.49K | 660.13K | 122.92B | 25.62K | 48.65K | 586.71K | 71.84K | 117.74K | 28.44K | 64.52K | 265.67K | 178.51K | 209.71K | 235.81K | 744.48K | 636.81K | 613.99K | 709.88K | 423.19K | 57.86K | 133.56K | 47.52K | 97.04K | 200.00K | 8.27K |
| Gross Profit Ratio | 100.00% | 98.28% | 99.50% | 44,609,100.00% | 59.34% | 70.15% | 93.27% | 65.97% | 67.42% | 51.78% | 96.74% | 98.29% | 99.07% | 91.51% | 82.09% | 96.99% | 81.89% | 88.80% | 83.49% | 81.39% | 29.83% | 72.71% | 85.15% | 257.88% | 100.00% | 67.39% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 873.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 491.60K | 494.18K | 454.11K | 497.20K | 525.78K | 607.61K | 896.45K | 855.89K | 1.14M | 1.15M | 786.85K | 1.54M | 1.35M | 968.02K | 1.61M | 2.07M | 1.98M | 2.45M | 1.47M | 1.12M | 1.39M | 989.22K | 1.61M | 1.90M | 3.00M | 0.00 |
| Other Expenses | 18.77K | 18.74K | 17.94K | 32.02K | 39.62K | 4.81K | 54.42K | 57.65K | 58.01K | 40.42K | 37.20K | 51.84K | 56.31K | 22.48K | 25.76K | 17.54K | 18.18K | 261.19K | 275.71K | 111.34K | 61.82K | 0.00 | 0.00 | 76.28K | 0.00 | 1.27M |
| Operating Expenses | 510.38K | 512.92K | 472.05K | 529.22K | 565.39K | 646.58K | 950.87K | 913.54K | 1.20M | 1.19M | 824.05K | 1.59M | 1.41M | 1.01M | 1.63M | 2.09M | 2.00M | 2.71M | 1.74M | 1.23M | 1.46M | 989.22K | 1.61M | 1.98M | 3.00M | 1.27M |
| Cost & Expenses | 510.38K | 517.73K | 475.35K | 529.22K | 582.94K | 667.28K | 993.19K | 950.59K | 1.26M | 1.22M | 826.22K | 1.59M | 1.41M | 1.03M | 1.69M | 2.11M | 2.14M | 2.79M | 1.88M | 1.32M | 1.59M | 1.04M | 1.61M | 1.92M | 3.00M | 1.27M |
| Interest Income | 0.00 | 1.16M | 1.21M | 1.19M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.89M | 1.16M | 1.21M | 1.19M | 1.00M | 1.01M | 1.56M | 1.27M | 915.21K | 755.49K | 588.10K | 173.78K | 127.15K | 272.80K | 355.30K | 300.32K | 241.78K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 18.77K | 18.74K | 17.94K | 32.02K | 39.62K | 38.97K | 54.42K | 57.65K | 58.01K | 40.42K | 37.20K | 51.84K | 56.31K | 41.94K | 25.76K | 17.54K | 18.18K | 261.19K | 275.71K | 111.34K | 61.82K | 65.58K | 78.80K | 76.28K | 0.00 | 8.86K |
| EBITDA | -476.52K | -43.28K | 206.02K | -221.64K | -657.76K | -558.96K | -217.23K | -724.70K | -1.02M | -1.13M | -722.33K | -1.27M | -1.18M | -758.31K | -1.37M | -1.33M | -1.35M | -1.84M | -757.55K | -693.63K | -1.34M | -790.08K | -1.48M | -1.81M | -2.80M | -1.25M |
| EBITDA Ratio | -2,382.60% | -78.66% | 31.05% | -80.43% | -1,123.02% | -830.56% | -51.23% | -720.04% | -585.53% | -2,049.80% | -1,083.02% | -470.64% | -650.40% | -330.88% | -477.67% | -173.14% | -173.20% | -265.64% | -89.34% | -133.40% | -734.27% | -430.11% | -2,652.14% | -4,797.53% | -1,400.00% | -10,174.54% |
| Operating Income | -490.38K | -238.43K | 188.08K | -253.67K | -539.78K | -597.94K | -364.16K | -841.70K | -1.08M | -1.17M | -759.53K | -1.32M | -1.23M | -800.24K | -1.40M | -1.34M | -1.37M | -2.10M | -1.03M | -804.97K | -1.40M | -855.66K | -1.56M | -1.88M | -2.80M | -1.26M |
| Operating Income Ratio | -2,451.88% | -85.37% | 28.35% | -92.06% | -1,250.47% | -862.24% | -57.89% | -772.99% | -618.75% | -2,123.40% | -1,138.79% | -489.82% | -681.65% | -349.18% | -486.65% | -175.03% | -175.54% | -303.39% | -121.52% | -154.81% | -720.78% | -465.82% | -2,793.35% | -5,000.24% | -1,400.00% | -10,246.74% |
| Total Other Income/Expenses | -1.89M | -986.46K | -1.26M | -1.19M | -1.16M | 756.28K | -1.46M | -1.21M | -909.66K | -760.10K | -583.92K | -128.44K | -132.26K | -272.80K | -349.71K | 0.00 | -241.78K | 9.00 | 0.00 | 0.00 | 88.00K | 0.00 | 0.00 | 0.00 | 2.80M | -16.54K |
| Income Before Tax | -2.38M | -1.22M | -1.07M | -1.45M | -1.70M | 158.34K | -1.83M | -2.05M | -1.99M | -1.93M | -1.34M | -1.45M | -1.36M | -1.07M | -1.75M | -1.34M | -2.10M | -2.10M | -1.03M | -804.97K | -1.31M | -855.66K | -1.56M | 0.00 | 0.00 | -1.27M |
| Income Before Tax Ratio | -11,912.20% | -438.56% | -161.70% | -525.34% | -3,943.22% | 228.33% | -290.42% | -1,883.41% | -1,139.64% | -3,507.33% | -2,014.28% | -537.34% | -755.05% | -468.22% | -608.38% | -175.03% | -269.63% | -303.39% | -121.52% | -154.81% | -675.41% | -465.82% | -2,793.35% | 0.00% | 0.00% | -10,381.51% |
| Income Tax Expense | 0.00 | 986.46K | 1.21M | 1.19M | 1.02M | 1.77M | 1.54M | 1.27M | 915.21K | 755.49K | 588.10K | 173.78K | 127.15K | 0.00 | 349.71K | 297.33K | 751.00 | -192.00 | -2.11K | -96.78K | -88.00K | 0.00 | 0.00 | 0.00 | 2.90M | -8.27K |
| Net Income | -2.38M | -2.21M | -2.29M | -2.64M | -2.72M | 158.34K | -1.83M | -2.05M | -1.99M | -1.93M | -1.34M | -1.45M | -1.36M | -1.07M | -1.75M | -1.64M | -1.61M | -2.10M | -1.03M | -804.97K | -1.31M | -855.66K | -1.56M | -1.88M | -2.90M | -1.27M |
| Net Income Ratio | -11,912.20% | -791.76% | -344.54% | -958.63% | -6,306.55% | 228.33% | -290.42% | -1,883.41% | -1,139.64% | -3,507.33% | -2,014.28% | -537.34% | -755.05% | -468.22% | -608.38% | -213.77% | -206.63% | -303.36% | -121.27% | -154.81% | -675.41% | -465.82% | -2,793.35% | -5,000.24% | -1,450.00% | -10,314.13% |
| EPS | -0.52 | -0.49 | -0.50 | -0.59 | -0.90 | 0.01 | -0.70 | -0.87 | -0.87 | -0.86 | -0.61 | -0.67 | -0.67 | -0.60 | -0.98 | -1.06 | -1.21 | -1.69 | -0.90 | -0.72 | -1.52 | -1.67 | -4.59 | -7.49 | -14.08 | -8.02 |
| EPS Diluted | -0.52 | -0.49 | -0.50 | -0.59 | -0.90 | 0.01 | -0.70 | -0.87 | -0.87 | -0.86 | -0.61 | -0.67 | -0.67 | -0.60 | -0.98 | -1.06 | -1.21 | -1.69 | -0.90 | -0.72 | -1.52 | -1.67 | -4.59 | -7.49 | -14.08 | -8.02 |
| Weighted Avg Shares Out | 4.54M | 4.54M | 4.54M | 4.49M | 3.01M | 30.09M | 2.60M | 2.37M | 2.28M | 2.23M | 2.21M | 2.17M | 2.03M | 1.80M | 1.78M | 1.55M | 1.32M | 1.24M | 1.15M | 1.11M | 864.38K | 513.17K | 339.84K | 251.26K | 205.92K | 157.83K |
| Weighted Avg Shares Out (Dil) | 4.54M | 4.54M | 4.54M | 4.49M | 3.01M | 30.09M | 2.60M | 2.37M | 2.28M | 2.23M | 2.21M | 2.17M | 2.03M | 1.80M | 1.78M | 1.55M | 1.32M | 1.24M | 1.15M | 1.11M | 864.38K | 513.17K | 339.84K | 251.26K | 205.92K | 157.83K |
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / October 3, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical...
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical research and...
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative topical / transdermal pharmaceutical research and development company, today announced the...
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX). The trials focus on the...
Source: https://incomestatements.info
Category: Stock Reports